Evidence map›Paper›PMID 40824417›Full record

ArticleAnnals of surgical oncology2025

Response-Adapted Oncologic Surgery in Cutaneous Squamous Cell Carcinoma: A Paradigm Shift Following Neoadjuvant Immunotherapy.

Dan Yaniv, Shorook Naara, Frederico Omar Gleber Netto, Haleigh Stafford, Jane Buell, Elizabeth Chiang, Ali Shahrukh, Sophie Li, Priyadharsini Nagarajan, Ehab Y Hanna and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dan Yaniv *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shorook Naara *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frederico Omar Gleber NettoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Haleigh StaffordSchool of Medicine, Baylor College of Medicine, Houston, TX, USA.
Jane BuellSchool of Medicine, Baylor College of Medicine, Houston, TX, USA.
Elizabeth ChiangSchool of Medicine, Baylor College of Medicine, Houston, TX, USA.
Ali ShahrukhThe University of Texas Medical Branch, Galveston, TX, USA.
Sophie LiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priyadharsini NagarajanDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ehab Y HannaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neil D GrossDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mamit@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies suggested that neoadjuvant cemiplimab can achieve a significant pathologic response in patients with cutaneous squamous cell carcinoma (CSCC). This was a retrospective cohort study (2018-2021) to determine whether response-adapted oncologic surgery (RAOS) can reduce surgical morbidity while maintaining oncological safety, thus offering a viable alternative to standard resection. PATIENTS AND

methodsA total of 41 patients with head and neck CSCC were treated with neoadjuvant cemiplimab followed by surgery, either RAOS or standard resection. The extent of the intended surgery (i.e., standard resection) was defined using a 10-mm margin from the clinically measured lesion. RAOS was defined as any resection smaller than the intended surgery. Main outcomes were surgical margins, local recurrence-free survival rates, organ preservation, need for free-flap reconstruction, and pathologic response, compared between the surgical groups.

resultsA total of 17 patients underwent RAOS and 24 patients underwent standard resection. Neoadjuvant treatment allowed for organ preservation in four (24%) patients in the RAOS group, and four (24%) patients in the RAOS group who were meant to have free-flap reconstruction did not need a free flap after resection. Clear margins were achieved in 16 (94%) patients in the RAOS group and 22 (92%) patients in the standard resection group (p = 0.3). The 2-year locoregional recurrence-free survival rate was 95% for the RAOS group and 90% for the standard resection group (p = 0.4).

conclusionsRAOS following neoadjuvant cemiplimab for CSCC appears oncologically safe and has similar survival outcomes to and less surgical morbidity than standard resection. Further prospective studies are needed to confirm these findings.

Identifiers

PMID40824417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.